Shortsellers Say Gingko BioWorks Is ‘Colossal Synthetic Biology Scam'
One Of 2021’s Biggest Biotech IPOs
The company claims its synthetic biology technology will revolutionize manufacturing but its share have dipped after the fraud allegations.
You may also be interested in...
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.
Company follows US office downsizing with similar plans for its global headquarters, once consumer health spin-out is complete in 2022.